Jonathan Yen-Wen Yu Sells 804 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $82.64, for a total transaction of $66,442.56. Following the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at $4,489,335.36. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total value of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Stock Down 1.5%

Disc Medicine stock traded down $1.17 during trading on Friday, hitting $78.84. 262,542 shares of the company were exchanged, compared to its average volume of 326,915. The business’s 50 day moving average is $74.60 and its 200 day moving average is $69.96. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a market capitalization of $301.96 million, a P/E ratio of -11.98 and a beta of 1.00. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. Analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming bought a new position in Disc Medicine during the second quarter valued at about $25,000. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine in the fourth quarter valued at about $33,000. Allworth Financial LP bought a new position in shares of Disc Medicine during the 2nd quarter valued at approximately $46,000. KBC Group NV bought a new position in shares of Disc Medicine during the 4th quarter valued at approximately $80,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Disc Medicine in the 4th quarter worth approximately $141,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IRON. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Wedbush reiterated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. HC Wainwright lifted their target price on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Morgan Stanley boosted their target price on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, June 15th. Finally, Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.00.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.